目的:优化灰树花子实体多糖硫酸酯化的工艺条件,探讨其硫酸酯化多糖的抗凝血活性。方法:灰树花子实体经过醇沉、碱提得到水不溶性多糖组分(Polysaccharide of Grifola frondosa,GF)。对硫酸酯化工艺中的反应温度、时间、原料比例条件进...目的:优化灰树花子实体多糖硫酸酯化的工艺条件,探讨其硫酸酯化多糖的抗凝血活性。方法:灰树花子实体经过醇沉、碱提得到水不溶性多糖组分(Polysaccharide of Grifola frondosa,GF)。对硫酸酯化工艺中的反应温度、时间、原料比例条件进行优化。通过活性部分的凝血活酶时间(APTT)、凝血酶时间(TT)和凝血酶原时间(PT)测定硫酸酯化多糖(Sulfated polysaccharide of Grifola frondosa,S-GF)的抗凝血活性。溶栓活性采用纤维蛋白板法测定。结果:最终确定硫酸酯化温度为60℃,时间3 h,GF∶氯磺酸=200 mg∶20 mL为最佳工艺条件。硫酸酯化多糖S-GF的取代度为2.01。经过Sephadex G50柱层析证明S-GF为均一组分。不同浓度的S-GF均能有效延长APTT和TT,并且随着浓度的增大,APTT和TT延长的时间越长,而对PT未见明显延长。结论:S-GF具有一定的抗凝血特性,并且是通过内源性凝血途径来实现抗凝血的,但是比肝素钠的抗凝血能力低。展开更多
Objective: Professional antigen-presenting dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic...Objective: Professional antigen-presenting dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic re- sistance. To evaluate whether DC-CIK cell-based therapy improves the clinical efficacy of chemotherapy, we reviewed the literature on DC-CIK cells and meta-analyzed randomized controlled trials (RCTs). Methods: We searched several databases and selected studies using predeflned criteria. RCTs that applied chemotherapy with and without DC-CIK cells separately in two groups were included. Odds ratio (OR) and mean difference (MD) were reported to measure the pooled effect. Results: Twelve reported RCTs (826 patients), which were all performed on Chinese patients, were included. Combination therapy exhibited better data than chemotherapy: 1-year overall survival (OS) (OR=0.22, P〈0.01), 2-year OS (OR=0.28, P〈0.01), 3-year OS (OR=0.41, P〈0.01), 1-year disease-free survival (DFS) (OR=0.16, P〈0.05), 3-year DFS (OR=0.32, P〈0.01), objective response rate (ORR) (OR=0.54, P〈0.01), and disease control rate (DCR) (OR=0.46, P〈0.01). Moreover, the levels of CD3+ T-lymphocytes (MD=-11.65, P〈0.05) and CD4+ T-lymphocytes (MD=-8.18, P〈0.01) of the combination group were higher. Conclusions: Immunotherapy of DC-CIK cells may enhance the efficacy of chemotherapy on solid cancer and induces no specific side effect. Further RCTs with no publishing bias should be designed to confirm the immunotherapeutic effects of DC-CIK cells.展开更多
基金supported by the Medical and Health Technology Development Project of Shandong Province,China(No.2014WS0351)
文摘Objective: Professional antigen-presenting dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic re- sistance. To evaluate whether DC-CIK cell-based therapy improves the clinical efficacy of chemotherapy, we reviewed the literature on DC-CIK cells and meta-analyzed randomized controlled trials (RCTs). Methods: We searched several databases and selected studies using predeflned criteria. RCTs that applied chemotherapy with and without DC-CIK cells separately in two groups were included. Odds ratio (OR) and mean difference (MD) were reported to measure the pooled effect. Results: Twelve reported RCTs (826 patients), which were all performed on Chinese patients, were included. Combination therapy exhibited better data than chemotherapy: 1-year overall survival (OS) (OR=0.22, P〈0.01), 2-year OS (OR=0.28, P〈0.01), 3-year OS (OR=0.41, P〈0.01), 1-year disease-free survival (DFS) (OR=0.16, P〈0.05), 3-year DFS (OR=0.32, P〈0.01), objective response rate (ORR) (OR=0.54, P〈0.01), and disease control rate (DCR) (OR=0.46, P〈0.01). Moreover, the levels of CD3+ T-lymphocytes (MD=-11.65, P〈0.05) and CD4+ T-lymphocytes (MD=-8.18, P〈0.01) of the combination group were higher. Conclusions: Immunotherapy of DC-CIK cells may enhance the efficacy of chemotherapy on solid cancer and induces no specific side effect. Further RCTs with no publishing bias should be designed to confirm the immunotherapeutic effects of DC-CIK cells.